Intended Use: MDM2 gene amplification
MDM2 is amplified in about 7% of all human cancers with the highest frequency of about 20% in soft tissue tumors. MDM2 might also have p53-independent transforming capabilities. Well-differentiated liposarcomas/atypical lipomatous tumors (WDL-ALT) and dedifferentiated liposarcomas are among the most common soft tissue tumors in adults. Both entities share the same genetic aberration, an amplification of the chromosomal region including MDM2.
Specimen Required
Paraffin-embed tissue (3–4-micron thick sections in positively charged/silanized slides).
Patient Preparation
- Sample collection: Tumor tissue (FFPE tissue block). Submit block/slides along with the corresponding Histopathology Report.
- Specimen preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin-embed tissue (3–4-micron thick sections). Fixative duration: 6-48 hours.
- Storage/Transport Temperature: Room temperature. Protect paraffin block from excessive heat. Also acceptable: Refrigerated. Ship in cooled container during summer months.
- Unacceptable Conditions: Paraffin block with no tumor tissue remaining. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Decalcified specimens. Specimens with fixation delayed for more than one hour. Tissue fixed or less than 6 hours of greater than 48 hours.
- Remarks
- Stability: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology
Fluorescence in situ Hybridization (FISH)
Sample received to report Turnaround time (TAT)
5 working days
Reference Interval
————-
Interpretive Data
The most recent WHO classification of Tumours of Hematopoietic and Lymphoid Tissues (Revised 5th edition) is used for interpretation criteria for evaluating MDM2 gene amplification status .
Resources
- Additional Technical Information
- Test Request Form
Sample Reports
- Enhanced Report
- See report